Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report

RATIONALE: While checkpoint inhibitors have revolutionized the treatment of melanoma, it is not known whether switching from one monoclonal antibody drug to another one would be justified in the case of a treatment failure. Herein, we report a case illustrating a durable response to pembrolizumab af...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepir, Tanja, Zaghouani, Mehdi, Roche, Stéphane P., Li, Ying-Ying, Suarez, Miguel, Irias, Maria Jose, Savaraj, Niramol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336603/
https://www.ncbi.nlm.nih.gov/pubmed/30633154
http://dx.doi.org/10.1097/MD.0000000000013804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336603/
https://www.ncbi.nlm.nih.gov/pubmed/30633154
http://dx.doi.org/10.1097/MD.0000000000013804

Ejemplares similares